In the first quarter of its 2024 fiscal year, the global beauty giant L’Oréal experienced a notable boost in performance, particularly driven by its dermatological beauty division. Overseeing dermo-cosmetic brands such as La Roche Posay, CeraVe, and Vichy, the division recorded a 21.9% increase in sales at constant exchange rates, reaching 2 billion euros.

During the period, the dermatological beauty division registered the highest growth within the group, surpassing the consumer products division (L’Oréal Paris and Garnier) with an 11.1% increase, the professional products division (Kérastase and Redken) with a 10.7% increase, while the luxury division (Lancôme, and Yves Saint Laurent Beauté) experienced a slight growth of 1.8%, impacted by declining sales in North Asia.

“The dermatological beauty division continues its momentum, growing 1.6 times faster than its dynamic market, once again demonstrating the relevance of its winning strategy. Continuing its global expansion, it achieves strong growth across all geographic regions, well balanced between developed and emerging markets,” the group stated in a press release.

La Roche-Posay remains the primary contributor to the division’s growth, while CeraVe also advances both in its domestic market, the United States, and internationally. In February, CeraVe garnered attention with a humorous commercial aired during the Super Bowl. This advertisement, employing humor and satire, featured Canadian actor Michael Cera as the fictitious visionary founder of the dermo-cosmetic brand launched in 2005 and acquired by L’Oréal in 2017.

It is worth noting that during the period, the division introduced Melasyl, a patented molecule designed to treat localized pigmentation disorders. This molecule is already available in La Roche-Posay’s Mela B3 range.

For the first quarter, L’Oréal announced on Thursday, April 18, an 8.3% increase in sales to 11.24 billion euros despite a decline in revenue in North Asia.